Clinical Trial Supplies Market worth $8.95 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets forecasts the global clinical trial supplies market to grow from $5.60 billion in 2026 to $8.95 billion by 2031, an 8.9% CAGR, supported by higher pharma/biotech R&D, decentralized trials and demand for cold-chain services. Logistics and distribution represented 27.2% of the market in 2025, while North America accounted for more than 41.4% of global revenue. Industry investment and consolidation are accelerating, including DHL's acquisition of CRYOPDP and UPS's approximately $1.6 billion purchase of Andlauer Healthcare Group to expand specialized healthcare logistics.

Analysis

This is a modestly positive read-through for integrated trial-supply platforms, but the reported market-growth rate is not independently investable absent evidence of contract wins, utilization, and pricing. TMO is best positioned to convert complexity into higher switching costs: bundling development, packaging, comparator sourcing, and distribution can lift wallet share while reducing sponsor vendor count. COR has a credible adjacency through specialty distribution, though its upside depends on whether trial-supply services become material enough to move consolidated operating margins rather than remaining a low-margin logistics extension.

UPS Healthcare is the clearest public logistics beneficiary, but acquisition-led healthcare growth should not be valued like a pure-play biologics logistics franchise. The key near-term issue is integration: specialized cold-chain networks require retained technical labor, validated lanes, and quality-system continuity; any service failure can create liabilities disproportionate to shipment revenue. CYRX faces a more nuanced setup—advanced-therapy shipment growth is favorable, yet scaled global networks can pressure pricing in less differentiated clinical lanes, making its chain-of-custody and ultra-low-temperature mix more important than broad trial-volume growth.

Over 1-3 months, this is primarily an earnings-call watch item rather than a catalyst. Watch TMO’s bioproduction/clinical-services bookings, UPS Healthcare revenue and margin disclosure, and CYRX revenue per shipment and gross-margin trajectory. Over 6-18 months, sponsor consolidation should favor providers that own validated depots and digital inventory data, but excess capacity built ahead of cell-and-gene therapy volumes could delay margin expansion; that would falsify the premium-multiple case for specialist logistics.

Contrarian view: consensus may over-credit logistics providers for nominal market growth while underestimating procurement pressure from large pharma and CROs. The economic profit pool should accrue to scarce, validated capacity and compliance workflow—not generic transport—so broad exposure via UPS is lower beta but less exposed to the highest-value portion of the spend.

Key Decisions for Investors

• Maintain or initiate a 6-12 month long TMO versus short ERF pair, sized market-neutral: TMO has greater ability to monetize end-to-end clinical supply integration, while ERF is more exposed to lower-differentiation testing and laboratory demand. Reassess if TMO reports weaker biopharma services bookings or if ERF delivers sustained organic-margin acceleration.
• Keep UPS on a 1-2 quarter watchlist rather than chase healthcare-M&A enthusiasm. Add only if management demonstrates healthcare revenue growth above the core package business without a deterioration in consolidated adjusted operating margin; a failed margin conversion would cap multiple upside.
• Avoid adding CYRX solely on broad clinical-trial growth. Consider a tactical long only after two sequential quarters of stable or improving gross margin alongside growth in high-value cryogenic/advanced-therapy shipments; downside is renewed price competition and fixed-cost under-absorption.
• Do not treat AND as a standalone listed-equity opportunity following its acquisition; use UPS disclosures as the public read-through for the acquired platform’s integration, retention, and cross-sell economics.